The influence of sodium metavanadate on the process of diabetogenesis in BB rats

• DOI: 10.1111/j.1582-4934.2003.tb00247.x
• Publication Date: 2007-05-01T12:11:04Z
• Authors: D. Cheta; Gabriela Orasanu; T. Nicolaie; Dana Iordachescu; S. Buligescu; C. Constantin; M. Hassanain; Anca Coman; Mihaela Enache; Raluca Negru; Valeria Tica; Delia Timofte; Daniela Gutu; C. Panaite
• Keywords: Blood Glucose; Male; 0301 basic medicine; Body Weight; Age Factors; Rats; 3. Good health; Prediabetic State; 03 medical and health sciences; Diabetes Mellitus, Type 1; Animals; Insulin; Female; Rats, Inbred BB; Vanadates

AbstractVanadium has been shown to be beneficial in the oral treatment of animal models of type 1 and type 2 diabetes. The aim of the study was to evaluate the short‐term effects of sodium metavanadate in prediabetic BB‐DP rats. To do this, 96 rats were divided into 4 equal groups. Groups VI, V2, V3 were treated with sodium metavanadate (0.1, 0.2 and 0.3 mg/ml respectively) and sodium chloride (0.5 mg/ml) in drinking water for 7 days. Group C received only sodium chloride (0.5 mg/ml). Blood glucose (BG), glycosuria, ketonuria, body weight and insulinemia were determined. The age of onset of diabetes was significantly higher for groups V2, V3 compared to group C, (p < 0.05) and depends on the metavanadate concentration (V3 vs. V1, p=0.006). The incidence of diabetes was lower in the rats treated with metavanadate than in the control group, but this difference was not statistically significant. In diabetic rats, the BG at the onset was higher in group C than in groups V, p < 0.05. Insulinemia, at the onset of the treatment as well as immediately after its cessation showed a drop in the treatment groups, proportionally to the dosage of vanadium, but later increased slowly and continuously until the end of the experiment. In conclusion, metavanadate delays the development of diabetes in BB‐DP rats, but does not prevent its onset. A milder form of diabetes occurs in diabetic rats treated with metavanadate. The effects depend on the metavanadate concentration and 0.2 mg/ml is preferable.